Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results from the Phase 3 ASCLEPIOS I/II Trials (P9-6.006)

Journal article

Peer reviewed

Jason Freeman, Silvia Delgado, Enrique Alvarez, Eric Thouvenot, Annette Okai, Alit Bhatt, Wenjia Wei and Tjalf Ziemssen

Neurology, Vol.102(17_supplement_1)

2024-04-09

Abstract

Abstract only

5 Record Views

Title: Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results from the Phase 3 ASCLEPIOS I/II Trials (P9-6.006)
Creators: Jason Freeman - Novartis
Silvia Delgado - University of Miami
Enrique Alvarez - University of Colorado Denver
Eric Thouvenot - Université de Montpellier
Annette Okai - Texas Neurology
Alit Bhatt - Novartis
Wenjia Wei - Novartis
Tjalf Ziemssen - University Hospital Carl Gustav Carus
Publication Details: Neurology, Vol.102(17_supplement_1)
Academic Unit: Miller School of Medicine; UMMG Department of Neurology; UMMG Dept of Neurology - Multiple Sclerosis Div
Language: English
Resource Type: Journal article
Record Identifier: 991032064117502976